enrolled. All patients were aged ≥20 years and had chronic HCV infection, defined as detectable HCV antibody (anti-HCV; Abbott HCV EIA 23, 24 Each patient received transient elastography (FibroScan, Echosens, Paris, France) to assess the stage of hepatic fibrosis. 25 In patients with confirmed cirrhosis, the severity was graded by Child-Pugh score. 
| Effectiveness
Patients received on-treatment effectiveness assessment by serum 
| Safety
The constitutional and laboratory adverse events (AEs) were assessed at each visit. The AEs were recorded by pre-specified case report form (CRF) and were graded according to the definition of (24) 90 ( HCV viral load at a cut-off value of 6 000 000 IU/mL, HCV genotype, and stage of hepatic fibrosis (Table S1 ). One HCV-1a patient in HIV/HCV coinfected group relapsed at off-therapy week 12. One HICV-1a and one HCV-2 patients in HCV-monoinfected group relapsed at off-therapy week 4; One HCV-1b patient was lost to follow-up at off-therapy week 12 in HIV/HCV-coinfected group and another HCV-2 patient was lost to follow-up at treatment week 12 in HCV-monoinfected group. The HCV RNA levels at the last visits were <LLOQ in both patients who were lost to follow-up.
| Resistance-associated substitutions
One hundred twenty-two (53.5%) and seven (3.1%) patients had baseline RASs in HCV NS5A and NS5B regions, respectively.
Patients with baseline NS5A or NS5B RAS had comparable SVR 12 rates to those without baseline RAS, regardless of HCV genotype or subtype (Table S2) Grade ≥3 (>5 9 ULN) 0 (0) 0 (0) a HIV/HCV-coinfected group: one patient with Child-Pugh B cirrhosis had oesophageal variceal bleeding at treatment week 10. HCV-monoinfected group: two patients with Child-Pugh B cirrhosis had esophageal and gastric variceal bleeding at treatment weeks 8 and 12, respectively; one with Child-Pugh C cirrhosis and the other one with Child-Pugh B cirrhosis had spontaneous bacteria peritonitis at treatment week 6 and week 8, respectively; one noncirrhotic patient had clavicle fracture at treatment week 2. All serious AEs were considered not related to the VEL/SOF or RBV, and treatment were not interrupted or discontinued.
b HIV/HCV-coinfected group: seven patients receiving boosted PI-based ART and two patients with Child-Pugh B cirrhosis. All these patients had ontreatment unconjugated hyperbilirubinaemia. HCV-monoinfected group: nine patients with Child-Pugh B or C cirrhosis, three patients with ChildPugh A cirrhosis, and one noncirrhotic patient with Gilbert's syndrome. All except three patients (Child-Pugh B cirrhosis in two and Child-Pugh C cirrhosis in one) had on-treatment unconjugated hyperbilirubinaemia. Among patients with decompensated cirrhosis receiving generic VEL/SOF plus weight-based RBV for 12 weeks, the SVR 12 rate was 92.9%, which was also comparable to the response rate (94%)
reported from ASTRAL-4 trial. 13 With regard to HCV viral decline during the first 4 weeks of treatment, the rates of viral load <LLOQ The prevalence of NS5A and NS5B RASs at specific amino acid location in our study was in line with a large-scale global survey of RASs for HCV, implying that the ethnicity was not an important factor for the RAS distribution. Regarding the therapeutic impact of baseline NS5A RAS, our data confirmed the results from a recent large-scale NS5A RAS analysis for HCV genotype 1-6 patients receiving brand-name VEL/SOF therapy in phase III trials that the SVR 12 rates were comparable, regardless of the presence or absence of NS5A RAS. 39 Furthermore, our study also confirmed the presence of baseline NS5B RAS did not affect the SVR 12 rate. [11] [12] [13] [14] One HIV/ HCV-coinfected patients in our study and two in ASTRAL-5 trial with poor HCV drug compliance did not reveal any NS5A or NS5B
RAS at the time of viral relapse, indicating that drug compliance should be strictly followed to improve the HCV care in these patients. 14 One HCV-1a monoinfected relapser with good drug compliance had the NS5A H58P RAS at the time of viral relapse.
Although the other HCV-2 monoinfected patient with baseline NS5A L31M RAS relapsed after treatment, no treatment-emergent NS5A or NS5B RASs were detected. Retreatment by the recently approved voxilaprevir (VOX)/VEL/SOF or glecaprevir/pibrentasvir (GLE/PIB) may be needed to achieve viral eradication. [40] [41] [42] Regarding the safety profiles, >99% of our HIV/HCV-coinfected However, 60% of our HCV-monoinfected patients with HBV coinfection developed HBV reactivation during generic VEL/SOF treatment, highlighting the need for HBV DNA monitoring to early detect clinical hepatitis or hepatic decompensation. 27, 43 In summary, generic VEL./SOF-based therapy for 12 weeks achieved comparably high SVR 12 rates and possessed excellent safety profiles in both HIV/HCV-coinfected patients and HCV-monoinfected patients.
